Photo: The White House from Washington, DC | Public domain | Wikimedia Commons
Trump Executive Order Fast-Tracks FDA Psychedelic Reviews And Directs VA Trials For PTSD
President Trump signed an April 18, 2026 executive order directing the FDA to fast-track reviews of certain psychedelics and spur VA trials. He signed it April 18, 2026 in the Oval Office, flanked by guests including podcaster Joe Rogan. The order names ibogaine, psilocybin, MDMA and LSD and directs the Food and Drug Administration to accelerate clinical reviews and consider special priority vouchers.
It also directs roughly $50 million toward federal research on ibogaine and opens a pathway under FDA's Right To Try rule for "desperately ill" patients. The VA is ordered to begin psychedelics research and participate in multiple trials, with at least five studies already planned in New York, California and Oregon. FDA officials say three psychedelics will enter a National Priority Voucher pilot to cut review times from months to weeks, a first for these drugs.
Advocates praised the order as a breakthrough for veterans and treatment-resistant mental illness, while researchers warned about limited data and patient safety, especially around ibogaine's cardiac risks. Reporting cites ibogaine as a Schedule I drug linked to at least 27 deaths from cardiac arrhythmias and a 2023 review that called heart risks "worrying." Scientific evidence for ibogaine is limited to small studies and one randomized trial, with only early larger trials underway, while other psychedelics have shown mixed but promising early results.
Early coverage and the signing event emphasized rapid access and hopeful testimony from veterans and supporters. Later reporting by outlets including NPR and Fox News shifted to focus on safety limits, limited evidence and the need for careful trials, prompting a more cautious mainstream tone. Broadcasts and social posts, from CBS clips to Face the Nation rundowns, made medical voices and public reaction central to the story.
Donald Trump
FDA and Drug Policy
Psychedelic Medicine
Drug Policy and Psychedelic Research
Veterans' Mental Health
This story is compiled from 8 sources using AI-assisted curation and analysis. Original reporting is attributed below. Learn about our methodology.
📌 Key Facts
- On April 18, 2026, President Trump signed an executive order in the Oval Office directing the federal government to fast-track research, review and potential approval of several psychedelics for PTSD, depression and addiction.
- The order specifically names ibogaine, psilocybin, MDMA and LSD as psychedelics the FDA should support in clinical trials and accelerate toward approval if found safe and effective; reporting notes ibogaine and psilocybin remain Schedule I under DEA rules.
- The administration directed $50 million in federal funding for psychedelic research (reported specifically for ibogaine) and opened a pathway for "desperately ill" patients to access ibogaine under the FDA's Right To Try rule.
- FDA Commissioner Makary said the agency will add three psychedelics to a National Priority Voucher pilot to cut review times from months to weeks, and that the FDA will begin the process to allow the first-ever ibogaine human trials in the United States.
- The executive order requires the Department of Veterans Affairs to begin psychedelics research and clinical trials, with reporting confirming at least five VA-participating trials in New York, California and Oregon and a focus on veterans who have not responded to SSRIs and talk therapy.
- Podcaster Joe Rogan personally lobbied the president about ibogaine, was present at the signing (standing behind Trump), and was publicly credited by the White House and reporting as a catalyst for the order.
- Scientists and public-health sources warned evidence for ibogaine is limited—small studies and one randomized trial, with larger trials only beginning—and that ibogaine carries cardiotoxicity risks linked in reporting to at least 27 deaths and prior pauses in NIH funding over cardiovascular concerns.
- Public reaction was mixed: veteran advocates and some medical commentators praised the potential for treatment-resistant patients, while drug-policy experts and clinicians cautioned about limited evidence, politicization, and the need for more research and careful dosing/safety oversight.
📰 Source Timeline (8)
Follow how coverage of this story developed over time
April 19, 2026
6:18 PM
Full transcript of "Face the Nation with Margaret Brennan," April 19, 2026
New information:
- Face the Nation’s rundown highlights Trump’s psychedelic executive order as part of a broader push to 'make America healthy again' and pairs it with news of his CDC director pick, framing both as a coordinated health agenda.
- The show teases an interview with former Surgeon General Jerome Adams to explain the implications of loosening psychedelic restrictions and the new CDC appointment, signaling that mainstream medical voices see both moves as consequential and politically fraught.
1:00 PM
Trump-backed plan could fast-track psychedelic therapies — here’s what to know
New information:
- Article reiterates that Trump signed an April 18, 2026 executive order to fast-track research, funding and potential FDA approval of ibogaine, psilocybin, LSD and MDMA for PTSD, depression and addiction.
- It states that the executive order will require the Veterans Affairs health system to begin psychedelics research and clinical trials and make those therapies available to veterans who have not responded to SSRIs and talk therapy.
- Provides on-the-record reaction from Jay Kopelman, former Marine Corps lieutenant colonel and CEO of Mission to Live Foundation, calling the order a pathway to expedited approval for treatment-resistant PTSD, TBI and depression.
- Includes comments from Fox medical contributor Dr. Marc Siegel saying psychedelics hold 'big potential' for severe depression and PTSD by modulating dopamine and serotonin but stressing the need for more research and careful dosing.
- Features praise from veteran advocate Juliana Mercer of Healing Breakthrough, who frames the move as a meaningful step for veterans who have tried years of therapy and medications without relief.
- Introduces critical perspective from drug-policy figure Kevin Sabet, who warns about limited evidence and politicization around ibogaine (partially visible in the excerpt but clearly present as a counterpoint).
April 18, 2026
6:56 PM
Trump signs order fast tracking review of psychedelics for mental health disorders
New information:
- NPR pins the signing to Saturday, April 18, 2026, and describes it as taking place in the Oval Office with specific participants present.
- The story specifies that Trump directed $50 million in federal funds to make certain psychedelics more accessible for mental health treatment.
- It clarifies that the executive order tasks FDA with fast tracking reviews of psilocybin and ibogaine and that ibogaine and psilocybin remain Schedule I drugs under DEA rules.
- FDA Commissioner Mary Makary is quoted as saying national priority vouchers for three psychedelics will allow approvals within weeks, and that this is the first time FDA has fast tracked any psychedelics.
- The article adds context on a 2025 JAMA study finding a single LSD dose eased anxiety and depression for months and restates national prevalence figures for serious mental illness, depression, and generalized anxiety disorder.
- It confirms that the Department of Veterans Affairs is participating in at least five psychedelic trials in New York, California, and Oregon.
5:00 PM
Trump signs executive order on psychedelic drugs — with Joe Rogan by his side
New information:
- Trump signed the executive order in the Oval Office with Joe Rogan standing directly behind him and publicly credited Rogan's call as a catalyst, saying Rogan told him 'We have to do something about this.'
- The order explicitly lists ibogaine, psilocybin, MDMA and LSD as psychedelics the FDA is directed to support in clinical trials and speed toward approval if found safe and effective.
- Rogan said he learned about ibogaine's potential from a podcast interview with Americans for Ibogaine CEO W. Bryan Hubbard and former Energy Secretary Rick Perry, both present at the signing.
- Trump joked about wanting ibogaine himself and cited a study he said showed major reductions in depression and anxiety symptoms within a month for people who took the drug.
- The article underscores that Rogan has recently criticized Trump on immigration, the Epstein files and the Iran war, yet appeared friendly with him at the signing, with Trump calling him a 'fantastic person.'
4:30 PM
Watch: Trump signs executive order easing U.S. restrictions on psychedelic research
New information:
- CBS clip confirms Trump signed an executive order specifically described as easing U.S. restrictions on psychedelic research.
- CBS explicitly frames ibogaine as a psychedelic used in some countries to treat post-traumatic stress disorder.
4:27 PM
Trump signs order to hasten review of psychedelics
New information:
- Confirms the order was signed Saturday, April 18, 2026, in the Oval Office.
- Details that FDA will issue new national priority vouchers for three psychedelics, cutting review times from months to weeks, marking the first time psychedelics receive this fast-tracking.
- States FDA is taking steps to clear the way for the first-ever ibogaine human trials in the United States.
- Quotes Trump promising to "dramatically accelerate" access and saying if the drugs are as good as advocates claim they will have a "tremendous impact."
- Reports that Joe Rogan personally texted Trump about ibogaine and that Trump replied, "Sounds great. Do you want FDA approval? Let's do it."
- Includes on-the-record enthusiasm from veteran Marcus Luttrell and explicit acknowledgment from researchers like Frederick Barrett about ibogaine's cardiotoxicity and past NIH funding being halted over cardiovascular risks.
1:46 PM
Trump signs order to research psychedelic used abroad to treat PTSD
New information:
- Executive order explicitly eases federal restrictions on ibogaine and is framed around post-traumatic stress disorder treatment, especially for veterans.
- Trump announces a $50 million federal research investment specifically for ibogaine.
- The administration will open a pathway for ibogaine use by 'desperately ill' patients under FDA's Right To Try rule.
- FDA Commissioner Marty Makary says three psychedelics will be added to the National Priority Voucher pilot program to cut review times.
- FDA will begin the process to allow human trials of ibogaine in the United States.
- Scientific evidence for ibogaine remains limited to small studies and one randomized trial, with only early larger trials underway.
- Ibogaine is a Schedule I drug associated with at least 27 deaths from cardiac arrhythmias, and a 2023 review called heart risks 'worrying.'